Sector: Health Care
IDEAYA BIOSCIENCES INC · Meeting: June 16, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Election of Three Class I Directors to Hold Office Until the 2029 Annual Meeting of Stockholders
Hata has served as CEO and director since 2015 and the company's 3-year total shareholder return of +50.5% outperforms the peer group median by +18.5 percentage points, well below the 65-percentage-point underperformance threshold required to trigger a vote against; no overboarding, attendance, or independence concerns were identified.
Hampton has served since June 2020 and brings strong oncology and genomics industry expertise; the TSR underperformance trigger does not apply given IDEAYA's strong positive 3-year return versus the peer group, and no overboarding, attendance, or independence concerns were identified.
Mackey has served since April 2022 and brings deep pharmaceutical research and development experience from Pfizer and other life sciences companies; the TSR underperformance trigger does not apply, and no overboarding, attendance, or independence concerns were identified.
All three Class I director nominees — CEO Yujiro Hata, Garret Hampton, and Catherine Mackey — pass all policy screens. IDEAYA's 3-year total shareholder return of +50.5% exceeds the compensation peer group median by +18.5 percentage points, far short of the 65-percentage-point underperformance threshold needed to trigger a vote against under the strong-positive-TSR tier. All directors attended at least 75% of meetings in 2025, none appear overboarded, and the board is composed entirely of independent directors except for the CEO.
CEO
Yujiro S. Hata
Total Comp
$9,512,640
Prior Support
78%%
CEO Yujiro Hata received total compensation of $9,512,640 in 2025, which is within a reasonable range for a biotech CEO at a $2.5 billion company given strong pipeline progress and a 42% one-year stock price gain. The pay program is heavily weighted toward variable, performance-linked compensation — base salary of $700,000 represents only about 7% of total pay, with the vast majority delivered through stock options that only have value if the share price rises, satisfying the policy's requirement that at least 50-60% of pay be performance-based. The prior say-on-pay vote received 78% support (above the 70% threshold), the company has a meaningful compensation recovery (clawback) policy, and there are no red flags around pay-for-performance misalignment given the company's 3-year total shareholder return of +50.5%.
Auditor
PricewaterhouseCoopers LLP
Tenure
9 yrs
Audit Fees
$1,465,000
Non-Audit Fees
$202,000
PwC has audited IDEAYA since fiscal year 2017 (approximately 9 years), well below the 25-year tenure threshold that would trigger a concern; non-audit fees (tax fees of $200,000 plus other fees of $2,000, totaling $202,000) represent about 13.8% of audit fees of $1,465,000, comfortably below the 50% threshold; and PwC is a Big 4 firm appropriate for a $2.5 billion market-cap company.
IDEAYA Biosciences' 2026 annual meeting presents three routine proposals — director elections, auditor ratification, and an advisory say-on-pay vote — all of which pass the applicable policy screens and receive a FOR vote determination. The company's strong stock performance relative to its peer group, a compensation program that is predominantly performance-linked through stock options, reasonable auditor fees and tenure, and clean governance practices support affirmative votes across the entire ballot.
21 companies disclosed in 2026 proxy filing
